Trial Profile
A Phase Ib Dose Escalation Study of POL6326 With Eribulin in Patients With Relapsed, Triple Negative and Hormone Refractory ER Positive Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Balixafortide (Primary) ; Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Proof of concept
- Sponsors Polyphor
- 31 May 2020 Results of final efficacy analyses from this trial, including assessment of dose-response, were presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 14 May 2020 According to a Polyphor media release, data from this trial will be presented at the American Society of Clinical Oncology (ASCO) 2020 virtual scientific program which is being held from May 29-31.
- 04 Jun 2019 Results of 18 and 24 months landmark overall survival data presented at the 55th Annual Meeting of the American Society of Clinical Oncology